Standard BioTools Q4 EBITDA misses estimates

Standard BioTools

24/02/2026 21:39

Overview

Life science tools firm's Q4 revenue fell 4% yr/yr

Adjusted EBITDA for Q4 missed analyst expectations

Company operationalized $40 mln in annualized cost savings

Outlook

Standard BioTools expects 2026 revenue between $80 mln and $85 mln

Standard BioTools emphasizes disciplined M&A to drive long-term shareholder value

Result Drivers

CONSUMABLES DECLINE - Lower consumables revenue in Q4 2025 was due to project funding declines in flow and microfluidics

INSTRUMENTS GROWTH - Instrument revenue grew 10% in Q4 2025, driven by strong growth in imaging

SERVICES REVENUE - Services revenue increased slightly due to higher demand from pharmaceutical customers, offset by decreased Field Services revenue

Company press release: ID:nGNX1MSt80

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$23.80 mln
Q4 EPS
$0.05
Q4 Net Income
$19.28 mln
Q4 Adjusted EBITDA
Miss
-$15.80 mln
-$12.10 mln (3 Analysts)
Q4 Gross Margin
47.80%
Q4 Adjusted Gross Margin
50.30%
Q4 Operating Income
-$24.60 mln
Q4 Pretax Profit
-$22.03 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Standard BioTools Inc is $1.55, about 39.6% above its February 23 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)